Compare Skyworks Solutions Inc (SWKS) vs 10X Genomics Inc (TXG) Price & Performance

Skyworks Solutions (SWKS) trades at $77.17, down 7.5% in the last session, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, but revenue and net income have declined year-over-year. The pending merger with Qorvo is a key development, with regulatory clearances obtained, targeting $500 million in synergies. Analyst consensus is a Buy with a $78.80 price target, slightly above the current price.

The outlook is mixed: the Qorvo merger offers growth potential and cost savings, but declining profitability and negative cash flow pose risks. Investor sentiment is cautious due to recent price volatility and earnings pressure. Upside depends on merger execution and market recovery, while downside risks include integration challenges and competitive pressures.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.